**Internamentos Hospitalares por Herpes Zoster em Portugal entre 2000 e 2010**

**Hospital admissions for Herpes Zoster in Portugal between 2000 and 2010**

Margarida Mesquita1

Filipe Froes2

1 – MD, Family Physician, MMed Geriatrics, Public Health PhDc, Escola Nacional de Saúde Pública, Universidade Nova de Lisboa, Portugal

2- MD, Pulmonologist, Hospital Pulido Valente, Centro Hospitalar Lisboa Norte. Public Health PhDc, Escola Nacional de Saúde Pública, Universidade Nova de Lisboa, Portugal

**Correspondence**:

Margarida Mesquita

mar.mes@gmail.com

M: +351 96 197 06 06

**Resumo**

Contexto:

O aumento da incidência de herpes zoster (HZ) e da nevralgia pós-herpética (PHN) estão associados ao envelhecimento da população. Estas patologias podem ser francamente debilitantes e ter um grande impacto na qualidade de vida dos doentes.

Numa população envelhecida como a portuguesa, é esperado que o impacto do HZ e da PHN aumentem. No entanto, não existe no país nenhum sistema específico de monitorização da doença e não foram encontrados dados epidemiológicos portugueses nas últimas décadas.

A vacina contra o HZ, já recomendada noutros países europeus, ainda não se encontra disponível em Portugal. Conhecer o impacto do HZ é importante para fundamentar medidas de saúde pública relacionadas com a vacinação.

Métodos:

Procedeu-se a uma análise retrospetiva da base de dados da Administração Central dos Sistemas de Saúde com a informação clínica codificada dos internamentos hospitalares de todos os indivíduos com o diagnóstico principal de HZ (ICD-9-CM 053) e que tiveram alta entre 2000 e 2010.

Resultados:

Em Portugal, entre 2000 e 2010, ocorreram 1706 internamentos hospitalares com o diagnóstico principal de HZ. A maioria dos doentes era idosa. 10.6% tinham formas potencialmente graves de imunocompromisso. A doença predominante de HZ sem complicações, seguido de HZ do sistema nervoso e oftálmico. A duração média dos internamentos foi de 9.3 dias, aumentando com a idade. A letalidade intra-hospitalar foi de 1%. Considerando o período de 2000-2009 e apenas a população adulta, a média anual da incidência dos internamentos hospitalares com o diagnóstico principal de HZ foi de 1.9 por 100000 habitantes, aumentando com a idade.

Conclusão:

Este estudo confirma que, em Portugal, as formas graves de HZ estão relacionadas com a idade e associadas a significativa morbilidade, mortalidade e utilização de recursos em saúde.

**Abstract**

Background:

Herpes zoster (HZ) and post-herpetic neuralgia (PHN) increasing incidence is related to ageing. These conditions can be very debilitating and have an important impact in patients quality of life.

In an ageing population like the Portuguese, is expected that the burden of HZ and PHN rises, nevertheless, a specific surveillance system for zoster does not exist in the country, and data regarding the incidence of HZ and the burden of the disease in Portugal in the last decades was not found.

In Portugal, the vaccine is still not available. Scaling the burden of disease is important to support public health policies regarding zoster vaccination.

Methods:

We carried out a retrospective analysis from encoded information from the Portuguese Ministery of Health database for hospital admissions which included all individuals with a primary diagnosis of Herpes Zoster (IDC-9-CM 053), who were discharged between 2000 and 2010.

Results:

In Portugal, between 2000 and 2010, 1706 hospital admissions with primary diagnosis of HZ occurred. The majority of the patients were elderly. 10.6% of the patients had potentially severe immunocompromise. The predominant disease was uncomplicated HZ, followed by nervous system and ophthalmic HZ. Mean hospital stay length was 9.3 days, increasing with age. There was a 1% case fatality rate. Considering the 2000-2009 period and the adult population only, the average annual incidence rate of hospitalization with primary diagnosis of HZ in Portugal was 1.9/100.000 inhabitants, increasing with age.

Conclusion:

This study confirms that, in Portugal, severe Herpes Zoster is related to ageing and associated with significant morbidity, mortality and health resources allocation.

**Introduction**

Herpes zoster (HZ), also known as shingles, is the clinical manifestation of the reactivation of latent varicella zoster virus (VZV), which as a primary infection causes varicella or chickenpox (1,2).

 HZ is a potentially serious and debilitating condition usually characterized by a unilateral vesicular rash and is usually accompanied by acute pain (2,3).

The most frequent and debilitating complication of HZ is post-herpetic neuralgia (PHN), a persistent neuropathic pain syndrome often defined as pain that persists for ≥90 days after the onset of HZ rash (2,4).

HZ, and particularly PHN, can have a devastating impact on patients’ quality of life, interfering with daily living activities and also affecting psychological and social domains (5,6).

The increasing incidence and severity of HZ and PHN can be associated with an age-related decline in VZV-specific cell-mediated immunity deriving from immunosenescense (3,7).

Approximately 25% of people will develop HZ during their lifetime (8) and this risk rate roughly doubles with each decade of life after 50 years (9) reaching 50% in those aged ≥85 years (5). Incidence rates range from approximately 3/1000 inhabitants per year at the age of 50 (7) to 9/1000 at the age of 65 (10) and 10/1000 at the age of 80 (7) (11).

 On average, 10–20% of HZ patients will develop PHN, which can persist for years or even decades after the HZ rash has gone, with rates of 25–50% reported in patients over 50 years old, depending on the definition used (2,12).

The second most frequent are the ophthalmic complications (13).

Studies refer need for inpatient care for 1.3% to 4.4 % of HZ cases (10,14), depending and almost 2% of PHN (14). Hospitalization rates increased with age, reaching more than 19% of the cases for 80+ patients (10).

While antiviral therapy reduces the severity and duration of HZ, it does not prevent PHN, which remains a poorly controlled condition, even after standard therapeutic approach (5).

In terms of zoster prevention, the existing vaccine showed to be safe and effective for immunization of immunocompetent individuals with no history of recent zoster (15). The preventive effect of the vaccine has been associated to a boost on host cell-mediated immunity to VZV (16).

In the elderly, vaccination significantly decreased shingles incidence, the development of PHN and its severity, and reduced the burden of both diseases (17,18).

The programmatic vaccination of the elderly population is actually considered cost-effective in some countries like Canada (19), US (20), UK (21), Netherlands (22) and is also recommended in Austria (23), Australia (24) and Greece (25).

Portugal assists to an accelerated demographic aging process. Portuguese individuals over 65 years old increased 18.2% in the last decade, from 16.4% of total population in 2001 to 19.0% in 2011. People reached an average life expectancy of 82.1 years for women and 76.1 for men between 2008 and 2010 (26).

In an ageing population like the Portuguese, is expected that the burden of HZ and PHN rises (2,3,7), nevertheless, a specific surveillance system for zoster does not exist in the country, and data regarding the incidence of HZ and the burden of the disease in Portugal in the last decades was not found.

In Portugal, the vaccine is still not available. Scaling the burden of disease is important to support public health policies regarding zoster vaccination.

This study aimed to characterize the incidence of hospital admission with HZ between 2000 and 2010 and analyze the patient’s characteristics over that period.

**Methods**

In this study we analyzed retrospectively all the hospital admissions encoded with zoster (ICD-9-CM 053) as primary diagnosis in public health system hospitals in mainland Portugal, between 2000 and 2010. Patients of all ages were included.

We searched for herpes zoster with meningitis (ICD 053.00), herpes zoster with unspecified complications of the nervous system (ICD 053.10), geniculate herpes zoster (ICD 053.11), trigeminal post-herpetic neuralgia (ICD 053.12), post-herpetic polyneuropathy (ICD 053.13), herpes zoster with other complications of the nervous system (ICD 053.19), eyelid dermatitis due to herpes zoster (ICD 053.20), keratoconjunctivitis due to herpes zoster (ICD 053.21), uveitis due to herpes zoster (ICD 053.22), herpes zoster with other ophthalmic complications (ICD 053.29), external otitis due to herpes zoster (ICD 053.71), herpes zoster with other specified complications (ICD 053.79), herpes zoster with unspecified complications (ICD 053.8) and herpes zoster without complications (ICD 05.39) in the Central Administration of the Health System (ACSS) of the Portuguese Ministry of Health database.

This database contains administrative and clinical data of all admissions to National Health hospitals, which covers almost the whole resident population of mainland Portugal. The clinical information, including diagnoses and procedures, is encoded from the details of the hospital discharge report by medical staff specially trained in hospital coding, using the International Classification of Diseases, 9th Revision - Clinical Modification (ICD-9-CM).

To obtain the relevant indicators for this study we adopted a descriptive statistical analysis approach focused on variables gender, age, immune status, type of HZ disease year of admission, length of hospital stay ad outcome.

The analysis of clinical information maintained patient anonymity.

The size of the population of mainland Portugal was obtained from the Info line of the National Institute of Statistics (26) and corresponds to the estimates of the resident population at the end of the year, subdivided by age and gender.

All the calculations presented were obtained using the Microsoft Excel spreadsheet and SPSS 18. Statistical tests used comprised T tests, Chi Square tests and Pearson correlation. The results of the used statistical tests were considered significant if p<0.05.

**Results**

*Patient characteristics*

In Portugal, here were 1706 hospital admissions with HZ encoded as the primary diagnosis between 2000 and 2010, with an annual frequency that ranged from 131 episodes in 2000 to 182 in 2010, with average of 155 episodes (SD 15.2) per year (Figure 1).

The 1706 cases with primary diagnostic of HZ represented 26.4% of the total 6474 episodes with HZ encoded as primary or secondary diagnosis during that period (Table 1).

From the 1706 episodes, 54% of the patients were women (N=922) and 46% men (N=784).

The average age was 57.1 years (SD: 25.2), with a median age of 64 years. The average age was 55.4 (SD: 25.3) for men and 60.0 (SD: 24.8) for women (p<0,001). The greatest age was 98 years for women and 99 for men and the lowest was 0 years for the both genders. (Figure 2)

Regarding the distribution of the episodes by age group, 12.4% were pediatric patients and 31.2% were adults (18-59 years). 69% of the patients were 50+, 56% were 60+, 41% were 70+ and 19% were 80+.

*Incidence rate*

Considering the 2000-2009 period and the adult population only, the average annual incidence rate of hospitalization with primary diagnosis of HZ in Portugal was 1.9/100000 inhabitants. This incidence rate showed a consistent increase with age, ranging from 0.5/100000 for the 18–29 age group to 0.7/100000 for the 30-49 age group, 1.7/100000 for the 50-64 age group, 2.8/100000 for the 65-74 age group, 5.5/100000 for the 75-84 age group and 8.8/100000 for the 85 and older age group.

*Type of disease*

Regarding to the type of HZ disease, 56.7% of the episodes were for HZ without complications, 21.0% for nervous system disease, 16.6% for ophthalmic disease, 9.8% for HZ with other complications and 3.2% for otologic disease. (Table 2)

Table 2 – Number of herpes zoster (HZ) admissions, average age, average hospital stay and mortality by type of HZ disease encoded as primary diagnosis.

*Immune status*

Regarding the immune status, 10.6% of the patients were immunocompromised (N=180). From these, 48.9% were HIV/AIDS patients (N=88), 40.6% were transplant patients (N=73) and 10.6% were oncologic patients on chemotherapy (N=19).

From the immunocompromised patients, 56.7% were male and 42.3% were female. The average age was 41.6 years (SD 25.4). 63% of the patients were 30 to 64 years old. When comparing to the immunocompetent patients, predominance of male gender (p=0.02) and younger age (p<0.001) was evident.

76.6% of these patients had uncomplicated HZ (N=136).

*Hospital stay*

The average length of stay for the admissions encoded with HZ as the primary diagnosis was 9.3 days (SD 8,2).

The hospital stay length showed a weak positive correlation with age (Pearson =0.195, p<0.001) and a significant difference between age groups (p=0.004). (Table 1)

Hospital stays >17 days (percentile 90) were more frequent (p<0.001) for patients 65+ (OR 2.48; CI95%1.75-3.52) and for patients with complicated HZ (OR 2.34; CI95%1.65-3.34).

The total 1706 admissions with primary HZ diagnosis accounted for 15898 days of inpatient treatment in Portugal during the 2000-2010 period. These correspond to an average of 1445 annual inpatient treatment days. Of these inpatient days, 65% were related to patients aged 60+.

*Outcome*

Patients who deceased in the hospital had an average age of 76.8 (SD 13.6), being significantly older (p<0.001) then the survivers.

Regarding the intra-hospitalar mortality for the admissions with primary diagnosis of HZ, this study revealed a 1% case fatality rate (N=17). From these patients, 9 were male. Ages ranged from 46 to 93 years, with mean age of 76.8 years (SD 18.1). From the deceased patients, 6 were admitted for uncomplicated HZ; 6 for HZ with nervous system complications including 3 with meningitis; 4 for HZ with ophthalmic complications and 1 for HZ with other complications.

**Discussion**

The last decade was marked by an evident demographic ageing, predisposing the population to an increase on HZ incidence and burden. In other hand, the first zoster vaccine became available. These two motives led to several studies regarding the incidence and burden of the disease in different settings (10,11,14,27-30).

This study focused on the most severe HZ episodes and showed that, in Portugal, during the 2000-2010 period, 1706 hospital admissions with primary diagnosis of HZ occurred. The majority of the patients were elderly. 10.6% of the patients had potentially severe immunocompromise. The predominant disease was uncomplicated HZ, followed by nervous system and ophthalmic HZ. Mean hospital stay length was 9.3 days, increasing with age. There was a 1% case fatality rate. Considering the 2000-2009 period and the adult population only, the average annual incidence rate of hospitalization with primary diagnosis of HZ in Portugal was 1.9/100000 inhabitants, increasing with age.

Our study has potencial limitations. The Portuguese Ministry of Health database is essentially administrative. The clinical information is coded from discharge documents; this work is carried out exclusively by medical doctors who have been formally trained in hospital coding, to make the process more rigorous. The Ministry of Health carries out regular audits, both internal and external, of this codification process.

We included patients of all ages in the study and didn’t exclude patients with underlying immunosuppressive conditions. We didn´t identify as immunocompromised the patients with oncologic disease not submitted to chemotherapy. Comparing to other studies, we present a lower percentage of immunocompromised patients, fact that can be related to this methodological difference.

Data for calculating incidence rates was only accessible for adults (>17 years) and for the period between 2000-2010, and so we could not calculate incidence rates for pediatric patients and for year 2011.

Apart from these limitations, the methodologies are similar to those which have been used in other countries (10,14,27).

One advantage of this study is that it covers a period of 10 years, a fact that can minimize the impact of years that deviate from the norm.

Comparing our study to the studies cited above, the main difference found was in the incidence rate of the episodes. We observed a 1.9/100000 inhabitants average annual incidence rate of hospitalization with primary diagnosis of HZ in Portugal. Although methods were not identical, this rate is lower than the observed in all the other studies, ranging from 4.4/100000 in England and Wales (10),to 8,4/100000 in Spain (30), 10.34/100000 in Italy (14), 16.1/100000 in the U.S (28) and 28/100000 in Australia, in patients aged 50+ (27).

Regarding the length of the hospital stay, our average was 9.3 days, within the average lengths observed in the other studies of 6.8 days in Australia, in 6,8 patients aged 50+ (27), 7.8 to 8 days in Italia (14,29), 8,3 days in Taiwan (11), and 10.8 days in the UK (10).

Relating to case fatality rate, our average (1%) was once more within the values observed in the other studies: 0.5% in the UK (10), 1.9% in the US (28) and 3.6% in Spain (30).

The relation between advancing age and the increased incidence of HZ requiring hospitalization, the increased in hospital stay length and the increased case fatality rate was observed in several studies (10,11,27). The proportion between genders and disease types was also consonant with what was observed in the other studies (11,27).

**Conclusion**

This study confirms that, in Portugal, severe Herpes Zoster is related to ageing and associated with significant morbidity, mortality and health resources allocation.

Knowledge of the incidence rate of HZ and PHN in primary care settings would be fundamental to completely scale the burden of disease in our country.

**References**

1. Lungu O, Annunziato PW, Gershon A, Staugaitis SM, Josefson D, LaRussa P, Silverstein SJ. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA 1995;92:10980–10984.

2. Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. J Public Health2012;20:441–451.

3. Arvin A.Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005;352:2266–2267.

4. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008;197(Suppl 2):S207–S215.

5. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001;32:1481–1486.

6. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neu-ropathy. Clin J Pain 2002; 18:350-4.

7. Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009;137:38–47.

8. Yawn BP , Saddier P , Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 82:1341–1349.

9. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605-9.

10. Brisson M, Edmunds WJ. Epidemiology of Varicella-Zoster Virus in England and Wales. Journal of Medical Virology 2003;70:S9–S14.

11. Lin YH, Huang LM, Chang IS. Disease burden and epidemiology of herpes zoster in prevaccine Taiwan. Vaccine 2010;28:1217–1220.

12. Scott FT, Leedham-Green ME, Barrett-Muir WY ,et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003;70(Suppl 1):S24–S30.

13. Volpi A. Severe complications of herpes zoster. Herpes 2007; 14 (Suppl 2): 35-9.

14. Gialloreti LE, Merito M, Pezzotti P et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study. BMC Infectious Diseases 2010, 10:230.

15. Arnou R, Fiquet A, Thomas A et al Immunogenicity and safety of ZOSTAVAX® approaching expiry potency in individuals aged ≥50 years. Human Vaccines 7:10, 1060-1065.

16. Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011 May ; 269(5): 496–506.

17. Zussman J, Young L. Zoster vaccine live for the prevention of shingles in the elderly patient.Clin Interv Aging. 2008 June; 3(2): 241–250.

18. Schmader KE, Johnson GR, Saddier P, et al. Effect of a Zoster Vaccine on Herpes Zoster-Related Interference with Functional Status and Health-Related Quality of Life Measures in Older Adults. J Am Geriatr Soc. 2010 September ; 58(9): 1634–1641.

19. Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008; 4:238–45. .

20. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007; 25:8326–37.

21. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009; 27:1454–67. .

22. van Lier et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Services Research 2010, 10:237.

23. Supreme Health Council. Vaccination Plan 2010 - Evidence-based recommendations of the Supreme Health Council. Austria. October 2009.

24. Pharmaceutical Benefits Advisory Committee - Public Summary Document - March 2008 PBAC Meeting. Australia,2008.

25. Greek Ministry of Health. 2012 National Vaccination Programme for Adults. Greece, 2011.

26. Instituto Nacional de Estatística. Estimativas Provisórias de População Residente, Portugal, NUTS II, NUTS III e Municípios. Instituto Nacional de Estatística (www.ine.pt).

27. Stein NA, Britt H, Harrison C, et al. Herpes Zoster burden of illness and health care resource utilization in the Australian population aged 50 years and older. Vaccine 2009;27:520-529.

28. Lin F, Hadler JL. Epidemiology of Primary Varicella and Herpes Zoster Hospitalizations:The Pre–Varicella Vaccine Era. The Journal of Infectious Diseases 2000;181:1897–905.

29. Gabutti G, Serenelli C, Sarno O, et al. Epidemiologic features of patients affected by herpes zoster: Database analysis of the Ferrara University Dermatology Unit, Italy. Médecine et maladies infectieuses 2010; 40: 268-272.

30. Gil A, San-Martín M, Carrasco P, et al. Epidemiology of severe varicella–zoster virus infection in Spain. Vaccine 2004;22: 3947–3951.

**Figures and Tables**

Figure 1 – Hospital admissions with primary diagnosis of HZ per year and subpopulation (pediatric patients were considered to be 0-17 years and adult 18-59 years).

Figure 2 – Hospital admissions with primary diagnosis of HZ per age.

Table 1 – Frequency of cases, gender distribution, length of hospital stay, case fatality rate and percentage of cases with HZ as primary diagnosis (HZ) per age group.

Table 2 – Number of herpes zoster (HZ) admissions, average age, average hospital stay and case fatality rate per type of HZ disease encoded.

**Tables**

Table 1 – Frequency of cases, gender distribution, length of hospital stay, case fatality rate and percentage of cases with HZ as primary diagnosis (HZ) per age group.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Age groups(years) | Gender | Frequency(N) | % of total N | Hospital stay (days) | Case Fatality Rate% | Primary diagnosis(%) |
| Masc. | Fem. |
| Mean | SD |
| 0-14 | 102 | 87 | 189 | 11,1% | 6.3 | 3.8 | 0,0% | 59,4% |
| 15-29 | 59 | 46 | 105 | 6,2% | 7.6 | 6.1 | 0,0% | 31,7% |
| 30-39 | 62 | 53 | 115 | 6,7% | 7.5 | 4.7 | 0,0% | 24,2% |
| 40-49 | 64 | 64 | 128 | 7,5% | 8,4 | 5.6 | 0,8% | 26,3% |
| 50-59 | 101 | 106 | 207 | 12,1% | 9.2 | 6.6 | 1,0% | 28,4% |
| 60-69 | 119 | 150 | 269 | 15,8% | 9.5 | 9.3 | 0,4% | 25,6% |
| 70-79 | 168 | 194 | 362 | 21,2% | 10.4 | 9.7 | 0,8% | 22,4% |
| 80-89 | 92 | 186 | 278 | 16,3% | 11.1 | 8.9 | 2,9% | 22,1% |
| 90-99 | 17 | 36 | 53 | 3,1% | 12.3 | 12.9 | 3,8% | 25,5% |
| Total | 784 | 922 | 1706 | 100,0% | 9.3 | 8.2 | 1,0% | 26,4% |

Table 2 – Number of herpes zoster (HZ) admissions, average age, average hospital stay and case fatality rate per type of HZ disease encoded.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  | Gender | Age (years) | Hospital Stay (days) | Mortality |
| ICD-9 Code | N | % | Masc | Fem | Mean | SD | Média | SD | N | Rate |
|  053.0 HZ with meningitis | 93 | 5,5% | 50 | 43 | 47,9 | 26,5 | 17,1 | 14,6 | 3 | 3,2% |
|  053.10 HZ with unspecified nervous system complication | 9 | 0,5% | 4 | 5 | 69,6 | 25,5 | 11,9 | 11,8 | 1 | 11,1% |
|  053.11 Geniculate HZ | 122 | 7,2% | 52 | 70 | 58,2 | 20,4 | 8,5 | 6,5 | 0 | 0,0% |
|  053.12 Postherpetic trigeminal neuralgia | 21 | 1,2% | 6 | 15 | 59,1 | 19,9 | 6,6 | 4,9 | 0 | 0,0% |
|  053.13 Postherpetic polyneuropathy | 44 | 2,6% | 19 | 25 | 69,6 | 16,1 | 11,4 | 9 | 1 | 2,3% |
|  053.14 HZ myelitis | 3 | 0,2% | 2 | 1 | 64,7 | 18 | 28 | 4 | 0 | 0,0% |
|  053.19 HZ with other nervous system complications | 64 | 3,8% | 28 | 36 | 63,2 | 18,8 | 10 | 9 | 1 | 1,6% |
| Total Nervous System HZ | 356 | 21,0% | 161 | 195 | 61,2 | 19,8 | 9,5 | 8 | 6 | 1,7% |
|  053.20 HZ dermatitis of eyelid | 148 | 8,7% | 68 | 80 | 57,8 | 27 | 8,6 | 7,2 | 3 | 2,0% |
|  053.21 HZ keratoconjunctivitis | 45 | 2,6% | 18 | 27 | 60,1 | 25,1 | 8,7 | 7 | 0 | 0,0% |
|  053.22 HZ iridocyclitis | 9 | 0,5% | 6 | 3 | 73,7 | 11,6 | 6,6 | 4 | 0 | 0,0% |
|  053.29 HZ with other ophthalmic complications | 82 | 4,8% | 43 | 39 | 60,9 | 25,5 | 9,8 | 7,8 | 1 | 1,2% |
| Total Ophtalmic HZ | 284 | 16,6% | 135 | 149 | 59,6 | 26 | 8,9 | 7,3 | 4 | 1,4% |
|  053.71 Otitis externa due to HZ | 54 | 3,2% | 22 | 32 | 56,5 | 22,8 | 9,1 | 6,1 | 0 | 0,0% |
|  053.79 HZ with other specified complications | 137 | 8,0% | 70 | 67 | 53,1 | 26,8 | 11,2 | 11,8 | 1 | 0,7% |
|  053.8 HZ with unspecified complication | 31 | 1,8% | 17 | 14 | 57,1 | 24,3 | 9,8 | 14,4 | 0 | 0,0% |
|  053.9 HZ without mention of complication | 844 | 56,7% | 379 | 465 | 56,4 | 25,9 | 8,2 | 5,8 | 6 | 0,7% |
| Total HZ | 1706 | 100% | 784 | 922 | 57,1 | 25,2 | 9,3 | 8,2 | 17 | 1,0% |